Biosimilar developers were displeased when the US FDA recently decided that it would no longer change the nonproprietary names of innovator biologicals that were initially approved without a random four-letter suffix. But Center for Drug Evaluation and Research (CDER) Director Janet Woodcock suggested that these objections could represent a disconnect between industry stakeholders and the prescriber and patient communities confronted with real-world problems.
In an exclusive interview with the Pink Sheet about the policy change, Woodcock asserted that practitioners are not worried about...
